摘要
铁死亡抑制蛋白1(ferroptosis-suppressor-protein 1,FSP1)是一种黄素蛋白,具有还原型烟酰胺腺嘌呤二核苷酸(NADH):泛醌(CoQ)10氧化还原酶活性,能够将CoQ10还原为二氢泛醌(CoQH_(2)),后者可以清除细胞内的活性氧和脂质自由基,达到抑制铁死亡的作用。因此,高表达FSP1的肿瘤细胞表现为对多种通过诱导细胞铁死亡发挥作用的抗癌药物的耐药;反之组织中FSP1表达水平的降低会增加其对铁死亡和氧化应激的敏感性,导致部分铁死亡相关疾病的发生和进展。
Ferroptosis-suppressor-protein 1(FSP1) is a flavin protein with nicotinamide adenine dinucleotide(NADH): coenzyme Q(CoQ)10 oxidoreductase activity can reduce CoQ10 to CoQH_(2), whichscavenges active oxygen and lipid free radicals in cells to inhibit ferroptosis. Therefore, tumor cells with high expression of FSP1 show resistance to a variety of anticancer drugs that act by reducing ferroptosis;in other words, the decrease of FSP1 expression in tissues will increase their sensitivity to ferroptosis and oxidative stress,leading to the occurrence and progression of ferroptosis-related diseases.
作者
沈惟钰
吴艳
卞涛
SHEN Weiyu;WU Yan;BIAN Tao(Department of Respiratory and Critical Illness,Wuxi People's Hospital Affiliated to Nanjing Medical University,Wuxi,Jiangsu 214000,China)
出处
《安徽医药》
CAS
2023年第3期425-428,共4页
Anhui Medical and Pharmaceutical Journal
基金
国家自然科学基金项目(82173472)
无锡市卫生健康委科研项目(M202032)。
